用富途牛牛查看Editas Medicine (EDIT)的股票价格、新闻、历史走势图、分析师评级、财务信息和行情。使用富途牛牛免佣金股票交易App进行交易。
EDIT Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced -82.84% Editas Medicine, Inc. price and volume Combination chart with 2 data series. Chart represents Editas Medicine, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has ...
The emotional state of those investors is what determines the price for Editas Medicine. If more investors feel that the Editas Medicine Stock will rise, it most likely will increase; and if more investors feel that the Editas price will fall, then it will fall. Thus, a stock's price ...
公司名称Editas Medicine 上市日期2016/02/03 发行价格16.00 成立日期2013 CEODr. Gilmore O’Neill, M.B. 所属市场纳斯达克 员工数量265 年结日12-31 公司地址11 Hurley Street 城市Cambridge 省份马萨诸塞州 国家美国 邮编02141 电话1-617-401-9000 网址http://www.editasmedicine.com 董事高管 姓名 职务 年...
Stock Price1.26 Revenue$0000 View About Editas Medicine Editas Medicine (EDIT) is a clinical stage genome editing company that focuses on developing treatments for serious diseases using gene editing technology. The company's main offerings include the development of CRISPR-based genomic medicines design...
Editas Medicine, Inc. (EDIT) growth grade and underlying metrics. Quant Ratings, revenue growth, EBITDA, EPS, cash flow, ROE, compounded, charts, and stocks comparison.
Editas Medicine pair trading Additional Tools for Editas Stock Analysis When running Editas Medicine's price analysis, check tomeasure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many differen...
作者: $Editas Medicine, Inc. Common Stock(EDIT)$已经涨到40,超过了之前所有投资机构的目标价
Topics discussed include increase in stock market of biotechnology company Editas Medicine Inc. which offers genome editing technology, medical device Tandem Diabetes Care Inc. increases after its upgraded shares, decrease in Peregrine Pharmaceuticals Inc. after announcing it is discontinuing its trial of...
Editas MedicineandVertex Pharmaceuticalshave forged a$50 million dealfor a licensing agreement of Editas’s Cas9 technology. In an announcement on Wednesday, Editas said Vertex will get a non-exclusive license the gene editing tech for use in medicines that target the BCL11A gene in sickle cell...